The Kotak Nifty Midcap 150 ETF, managed by Kotak Mahindra Asset Management Company Limited, aims to replicate the Nifty Midcap 150 Index, focusing on market cap weighted investments.

This ETF employs a tracking approach to mirror the Nifty Midcap 150 Index TRI, though it recognizes potential tracking errors that may affect performance outcomes.

The portfolio is concentrated in the Pharmaceuticals and Biotechnology sector, with top holdings including Lupin Ltd. and Glenmark Pharmaceuticals, indicating a sector-specific risk profile.

In the past year, the fund has delivered a robust return of 16.1%, with a tracking error of 1.33%, showcasing its performance consistency relative to the benchmark.

With an AUM of ₹4.58 Cr and an expense ratio of just 0.1%, this ETF provides an efficient investment vehicle for accessing midcap equities with relatively low operational costs.